Autoimmune Disease

Drago et al. (2006, Scandinavian Journal of Gastroenterology) exposed intestinal biopsy samples from both coeliac and non-coeliac individuals to gliadin peptides. Zonulin release and increased intestinal permeability occurred in all samples, with coeliac tissue showing greater magnitude but non-coeliac tissue showing the same directional response. Hollon et al. (2015, PLoS ONE) confirmed: gliadin increased intestinal permeability in all groups tested, including healthy controls.

This is because gliadin binds to the CXCR3 chemokine receptor on enterocytes, triggering MyD88-dependent zonulin release. Zonulin disassembles tight junction proteins (claudin, occludin, ZO-1), opening paracellular spaces to molecules up to 5,000 daltons. This is an innate immune response, not an adaptive one: it does not require prior sensitisation or HLA-DQ2/DQ8 genotype. Every human gut responds to gliadin with some degree of increased permeability.

The clinical distinction between coeliac disease, non-coeliac gluten sensitivity and "healthy" is one of degree, not of mechanism. The 99% of the population told they "don't have coeliac" are still experiencing gliadin-induced tight junction disruption with every wheat exposure. The question is not whether damage occurs but whether the individual's repair capacity exceeds the rate of insult.

Hahn et al. (2022, BMJ) reported the autoimmune outcomes of the VITAL randomised trial (25,871 US adults, mean age 67). Participants randomised to vitamin D3 (2,000 IU daily) had a 22 per cent reduction in confirmed autoimmune disease incidence over 5.3 years compared with placebo (HR 0.78, 95% CI 0.61 to 0.99). The effect strengthened over time: when the first two years were excluded (allowing for the latency of disease development), the reduction was 39 per cent. Conditions prevented included rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, inflammatory bowel disease and psoriasis.

Vitamin D is not merely a bone mineral. It is a secosteroid hormone that binds to the vitamin D receptor (VDR), which is expressed on virtually every immune cell: T-cells, B-cells, macrophages, dendritic cells and natural killer cells. Vitamin D promotes immune tolerance by expanding regulatory T-cells, suppressing Th17 differentiation (the primary driver of autoimmune tissue destruction), reducing B-cell antibody production and shifting dendritic cells towards a tolerogenic phenotype. The current UK RDA of 400 IU was set to prevent rickets, not to maintain immune function. The VITAL trial used 2,000 IU. Many researchers consider 4,000 to 5,000 IU necessary for optimal serum levels (40 to 60 ng/mL).

The deficit these trial doses corrected was created by the indoor lifestyle that strips cutaneous synthesis from October to March. Sun exposure remains the primary route; fermented cod liver oil and oily fish carry the secondary route in the fat-soluble matrix the immune system was designed to receive. Supplementation is the pharmacological proxy for what the body should already be making.

Fasano (2011, Physiological Reviews) demonstrated that gliadin, the prolamin fraction of wheat gluten, triggers release of zonulin in the intestinal epithelium of both coeliac and non-coeliac individuals. Zonulin reversibly disassembles the tight junctions between enterocytes, increasing intestinal permeability ("leaky gut"). In coeliac patients, gliadin exposure increased permeability by approximately 70 per cent. In non-coeliac subjects, the increase was smaller (approximately 20 per cent) but still significant. The effect was dose-dependent and occurred within 15 to 30 minutes of exposure.

Tight junctions are the primary barrier between the gut lumen (which contains bacteria, food antigens, toxins and partially digested proteins) and the systemic immune system. When permeability increases, large molecules cross the epithelial barrier and encounter the gut-associated lymphoid tissue (GALT), which houses 70 per cent of the body's immune cells. The immune system mounts responses against these foreign molecules, and if any resemble self-proteins (molecular mimicry), autoimmune reactions follow. Fasano's group has linked zonulin-mediated permeability to Type 1 diabetes, multiple sclerosis, ankylosing spondylitis and rheumatoid arthritis. Modern wheat varieties contain significantly more gliadin than ancient grains, and wheat consumption has increased substantially since industrialisation.

Darlington et al. (1986, The Lancet) randomised 53 patients with active rheumatoid arthritis to either a strict elimination diet (starting with a few hypoallergenic foods and gradually reintroducing one food per week) or a control diet for 6 weeks. In the elimination group, 24 of 53 patients (46 per cent) experienced clinically significant improvement: reduced joint pain, morning stiffness, grip strength improvement and reduction in erythrocyte sedimentation rate (ESR). When specific trigger foods were reintroduced, symptoms reliably recurred within 24 to 48 hours. The most commonly identified triggers were wheat, corn, dairy, beef, nightshades and citrus.

The mechanism is immune complex deposition. When partially digested food proteins cross a permeable intestinal barrier, they bind circulating antibodies to form immune complexes. These complexes deposit in synovial tissue (joint lining), activating complement and triggering inflammatory cascades that destroy cartilage and bone. Each individual has a unique set of food-specific IgG antibodies based on their intestinal permeability pattern and immune history. Standard rheumatology practice treats the downstream inflammation (NSAIDs, DMARDs, biologics) without investigating the upstream dietary trigger. The 46 per cent response rate to diet alone exceeds or matches the response rates of most first-line RA medications.

Lerner et al. (2015) in Autoimmunity Reviews reviewed the global epidemiological literature and found that the incidence of autoimmune diseases has been increasing by approximately 19 per cent per decade since the mid-twentieth century. Type 1 diabetes has increased 3 to 5 per cent annually in Europe for 50 years (Patterson et al. 2009, EURODIAB). Coeliac disease prevalence has increased 4-fold in 50 years in the US (Rubio-Tapia et al. 2009). Multiple sclerosis incidence has doubled in women since the 1970s (Orton et al. 2006).

This is because autoimmune disease occurs when the immune system loses the ability to distinguish self-tissue from foreign antigen. Three conditions must be present simultaneously (Fasano 2012): genetic susceptibility (which has not changed), an environmental trigger (which has changed dramatically) and intestinal permeability (which has increased). The environmental triggers include molecular mimicry from food proteins (gliadin resembling cerebellar peptides), adjuvant-mediated immune activation, vitamin D deficiency (immunomodulatory), altered microbiome composition and xenobiotic chemical exposure.

The 19 per cent per decade rate eliminates genetic causation: the human genome does not change that quickly. The increase maps precisely onto the period of industrialised food processing, widespread antibiotic use, caesarean birth rates, indoor living, soil depletion and chemical proliferation. Autoimmune disease is not a genetic lottery. It is an environmental poisoning of immune regulation, with the gut as the primary entry point and the microbiome as the first casualty.

Catassi et al. (2013, Annals of Medicine) proposed diagnostic criteria for non-coeliac gluten sensitivity (NCGS): symptom resolution on gluten-free diet, relapse on double-blind placebo-controlled gluten challenge, negative coeliac serology, normal villous architecture. Prevalence estimates range from 0.5 to 13% depending on population and criteria, with 6% as the most cited midpoint (Volta et al., 2014, BMC Medicine).

This is because the binary diagnostic framework, coeliac versus not coeliac, leaves no clinical category for the millions who experience measurable symptoms from gluten without meeting the arbitrary threshold of villous atrophy. NCGS patients show innate immune activation (elevated toll-like receptor expression), systemic inflammation (elevated IL-6, IL-8) and neurological symptoms (brain fog in 42% of cases) without the adaptive immune markers used to diagnose coeliac disease.

An estimated 1 in 17 people worldwide experience clinically significant reactions to modern wheat, yet the gastroenterological establishment spent decades dismissing NCGS as psychological. The condition was only formally recognised by consensus in 2011 (Sapone et al., BMC Medicine). Millions were told their symptoms were imaginary while the mechanism, gliadin-induced permeability, had been documented since 2006.

Rubio-Tapia et al. (2009) tested archived blood samples from 9,133 Air Force recruits collected in 1948-1954 for tissue transglutaminase antibodies (tTG-IgA) and found a coeliac disease prevalence of 0.2 per cent. When they tested a matched cohort of modern subjects, the prevalence was 0.9 per cent: a 4.5-fold increase. The increase was not due to improved detection; the same antibody test was applied to both cohorts. The archived cohort also had lower all-cause mortality, with undiagnosed coeliac carriers having a fourfold higher death rate.

This is because the wheat consumed by the 1950s cohort was a different crop. Pre-Green Revolution wheat varieties had lower gliadin content, less aggressive gluten proteins and were grown without glyphosate desiccation. The combination of modern dwarf wheat (10 times more immunogenic gliadin), glyphosate-damaged gut permeability and depleted gut microbiome diversity has created a perfect storm for autoimmune activation in genetically susceptible individuals.

Coeliac disease is the visible peak of a larger iceberg. For every diagnosed coeliac patient, an estimated six to eight have undiagnosed non-coeliac gluten sensitivity with systemic inflammatory consequences: joint pain, brain fog, dermatitis, anaemia and neuropathy. The HLA-DQ2 and DQ8 risk alleles are carried by 30 to 40 per cent of the population and have not changed in frequency. What changed is the trigger: the food.

Summers et al. (2005, Gut) enrolled 29 patients with active Crohn's disease in an open-label trial of Trichuris suis ova (TSO, pig whipworm eggs). Patients ingested 2,500 ova every three weeks for 24 weeks. At week 24, 21 of 29 patients (72 per cent) achieved clinical remission (CDAI below 150) and 23 of 29 (79 per cent) achieved clinical response (100-point CDAI reduction). The treatment was well tolerated with no serious adverse events.

The mechanism is immune recalibration through the hygiene hypothesis. Helminth parasites co-evolved with human immune systems for millions of years. They survive by secreting molecules that promote regulatory T-cell expansion, shift the immune response from Th1/Th17 (pro-inflammatory, autoimmune) to Th2/Treg (anti-inflammatory, tolerogenic) and increase production of IL-10 and TGF-beta (anti-inflammatory cytokines). The near-total elimination of helminth exposure in developed countries since the mid-twentieth century removed a major immunoregulatory input. The geographic distribution of autoimmune disease inversely correlates with helminth prevalence: where worms disappeared, autoimmune diseases appeared.

The EURODIAB study tracking twenty nine European countries found type 1 diabetes incidence rising by 3.4% per year, with the steepest increases in children under five years of age.

This is a non-genetic rate of change: the human genome cannot shift over two decades, so the driver must be environmental. Early gut microbiome composition, formula feeding rates and antibiotic exposure are the leading candidates.

If the trend continues at current rates, incidence in European children will double within fifteen years, representing a public health challenge that current dietary guidance is not designed to address.

Fasano (2012) in Clinical Reviews in Allergy and Immunology proposed the triad model of autoimmunity: genetic predisposition, environmental trigger and increased intestinal permeability must all be present for autoimmune disease to develop. Subsequent research confirmed that every autoimmune condition studied (type 1 diabetes, coeliac disease, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, ankylosing spondylitis, lupus) demonstrates increased intestinal permeability when measured by lactulose-mannitol ratio or serum zonulin levels.

This is because the intestinal epithelium is a single-cell-thick barrier separating the body's internal environment from the contents of the gut lumen (food antigens, bacterial products, toxins). Tight junction proteins (claudins, occludin, zonula occludens) seal the gaps between enterocytes. Zonulin, discovered by Fasano's lab, is the only known physiological modulator of tight junctions: it opens them. Gliadin (a wheat protein) and pathogenic bacteria both trigger zonulin release. When tight junctions open excessively, partially digested food proteins, bacterial lipopolysaccharides and other antigens enter the bloodstream, triggering immune responses.

If increased intestinal permeability is a prerequisite for autoimmune disease, and intestinal permeability is modifiable (through diet, microbiome restoration, removal of permeability triggers), then autoimmune disease may be preventable and in some cases reversible by restoring barrier function. Fasano demonstrated that removing the environmental trigger (gluten in coeliac disease) restores intestinal permeability and halts autoimmune destruction of intestinal villi.

A Danish national birth cohort following over five hundred thousand children found that antibiotic exposure before age one was associated with a twofold increase in the risk of developing inflammatory bowel disease.

This is because the infant gut microbiome is in a critical developmental window during the first year of life. Antibiotic disruption at this stage reduces colonisation diversity in ways that persist for years, weakening the intestinal barrier and promoting immune dysregulation.

The dose-response is clear: each additional antibiotic course increased IBD risk incrementally, and broad-spectrum antibiotics caused greater disruption than narrow-spectrum alternatives.

Vitamin D functions as a steroid hormone that regulates gene expression in over 200 cell types including immune cells. Vitamin D receptor expression is found on T lymphocytes, B lymphocytes, macrophages and dendritic cells. When activated, it promotes differentiation of T-regulatory cells, which suppress inflammatory immune responses and maintain immune tolerance to self-tissue. Deficiency disrupts this regulatory function and shifts immune balance toward pro-inflammatory Th17 responses.

A 2012 meta-analysis of thirteen prospective cohort studies found that individuals with the highest vitamin D levels had a fifty percent lower risk of multiple sclerosis compared to those with the lowest levels. Latitude gradients in MS incidence track closely with sun exposure and serum vitamin D levels across populations. Type one diabetes, rheumatoid arthritis, lupus and inflammatory bowel disease all show consistent inverse associations with vitamin D status in meta-analyses. NHANES data for England show that forty percent of adults are vitamin D deficient by winter.